Loading...
Loading...
AtriCure, Inc.
ATRC, a medical device company and a leader in
cardiac surgical ablation systems for the treatment of atrial fibrillation, or
AF, and systems for the exclusion of the left atrial appendage, in
anticipation of investor meetings in San Francisco during the week of January
7, is announcing preliminary financial results for fourth quarter and full
year 2012.
Preliminary revenue for the fourth quarter of 2012 is expected to be
approximately $18.4 million, reflecting growth of approximately 9.5% over the
fourth quarter of 2011. Based on these preliminary estimates, revenue from
U.S. customers is expected to be $13.7 million, reflecting growth of 10.2%,
and revenue from international customers is expected to be $4.7 million,
reflecting growth of 7.7%, or 10.0% on a constant currency basis.
Preliminary revenue for full year 2012 is expected to be $70.2 million,
reflecting year over year growth of 9.1% over full year 2011.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in